ArticleCureus2026
Factor XIII Supplementation Suppresses Recurrent Hemorrhages Due to Acquired Factor XIII Deficiency Secondary to Severe Acute Pancreatitis: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemorrhagic complications associated with severe acute pancreatitis significantly worsen the prognosis. Acquired factor XIII (FXIII) deficiency can lead to delayed tissue repair and associated recurrent bleeding, yet its clinical impact in the context of pancreatitis remains poorly understood. A 69-year-old woman with severe acute pancreatitis developed recurrent hemorrhagic shock due to multiple arterial bleeding episodes, including the splenic and left gastric arteries. Despite repeated transcatheter arterial embolization and massive blood transfusions, hemorrhagic events recurred during the subacute phase. Laboratory investigations revealed an acquired FXIII deficiency with FXIII activity levels of 56-59%. Repeated administration of FXIII concentrates administration suppresses the hemorrhagic complications gradually. This report suggests that FXIII concentrate administration may be a beneficial therapeutic option for managing recurrent hemorrhagic complications and stabilizing the clinical course in patients with severe acute pancreatitis and acquired FXIII deficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.